NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000 , meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
Aug 14, 2018 . The NeoChord device, in illustration, is inserted in the beating heart through a small incision, guided by echocardiography “While the heart is beating, you make a small incision under the patient’s left nipple, insert the device, and implant the artificial chords to the mitral valve,” says Dr. El-Eshmawi, the site Principal Investigator for the study.
Show more
See More
Worrell also supported NeoChord’s graphic design assets, which included branding, logos, and packaging design. Worrell’s efforts in navigating the complexity of the regulatory pathway turned a novel idea into an established medical brand positioned for long-term success. UPDATES
Show more
See More
NeoChord Device Patent. NeoChord, Inc. has a pending patent (US 2009/0105751) for a device designed to perform minimally invasive repair of a valve leaflet in a beating heart. The NeoChord device, invented by John Zentgraf, is an existing solution to deliver and implant artificial chordae tendineae to the mitral valve leaflet and is likely the most promising current solution.
Show more
See More
prefer using the loop NeoChord technique for most patients with MV prolapse.7-9 A variety of approaches to expose the MV have been described, including minimally invasive approaches with an array of cannulation strategies for cardiopulmonary bypass.8,10-12 The advantages and disadvantages of mini-
Show more
See More
Jan 08, 2013 . Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. By Adam Pick on January 8, 2013. As we continue to monitor the newest technologies enhancing valvular therapy, I though you might like to know that the NeoChord mitral valve repair system recently received a CE mark for use in Europe. This unique device, which is not FDA approved in ...
Show more
See More
NeoChord DS1000. Heart valves are held in place with string-like tendons that can often stretch or break leading to serious heart conditions. Before the NeoChord DS1000, surgeons had to put the heart on bypass to manually place sutures in a very invasive and dangerous procedure. The DS1000 is a single-use, hand-held solution for a minimally ...
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Show more
See More
Oct 16, 2009 . Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
Study design. This observational study was conducted at Padua and Vilnius University Hospitals, from February 2013 to June 2014. All data were prospectively collected in the NeoChord International Independent Registry (NIIR). All patients were candidates for conventional MV repair surgery, according to the current guidelines . Patients were considered eligible for NeoChord …
Show more
See More
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation. In contrast, most mitral valve repair procedures are performed through a 3 to 10-inch chest
Show more
See More
Jan 18, 2011 . NeoChord Inc., which is developing innovative medical devices for the heart’s mitral valve, raised $1 million to tide it over before a …
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency. The NeoChord Artificial Chordae Delivery System, Model DS1000 , meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
Transapical off-pump MVR with NeoChord implantation is performed with the NeoChord DS1000 system using two-dimensional (2D) and three-dimensional (3D) transesophageal echocardiographic (TEE) guidance for prolapse and/or flail treatment of the anterior and/or posterior mitral leaflets ( Figure 1A ). 4-6 Figure 1.
Show more
See More
Jan 29, 2013 . Safety and Performance Study of the NeoChord Device (TACT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Show more
See More
Jun 17, 2016 . Randomized Trial of the NeoChord DS1000 System Versus Open Surgical Repair (ReChord) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by …
Show more
See More
The NeoChord nomogram is a plot that displays the predicted probability of achieving ≤ mild MR at follow-up and is intended for support in the patient selection decision-making process. The nomogram is a prognostic tool that predicts the probability of a successful MV repair with the NeoChord procedure at early and late follow-up periods.
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. This unique device, which is not FDA approved in America, enables minimally invasive implantation of artificial chordae using a catheter-based approach. If you did not know, the chordae support the mitral valve leaflets as they open-and-close to move the blood through your heart.
The first 50 patients of the TACT study are scheduled to undergo the NeoChord procedure during the first three months of this year. Dr. Giovanni Speziali, one of the proctors of the study from the University of Pittsburgh Medical Center, stated: